Home ›
Liver Cancer Trials ›
NCT06652243
Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma
This is a single-arm, open-label study of safety, tolerability, and anti-cancer activity of SN301A (an off-the-shelf CAR NK cell therapy) in patients with glypican-3 (GPC3)-positive advanced hepatocellular carcinoma.
Trial Details
NCT ID NCT06652243 Phase EARLY_PHASE1
Sponsor Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Status RECRUITING
Cancer Type Liver Cancer
Interventions Locations (sample) Shanghai, Shanghai Municipality, China|31.22222,121.45806
Key Eligibility Criteria
Signed written informed consent (ICF) and capable of complying with protocol-specified visits and related procedures; Age ≥ 18 years and ≤ 70 years, male or female; According to the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer of CSCO in 2024, hepatocellular carcinoma was Diagnosed and GPC… Barcelona Clinic Liver Cancer (BCLC) stage determined to be unresectable Stage B or C hepatocellular carcinoma, including: disease progression foll… For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Liver Cancer Trials on Trialify →